Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Quantification of neutralizing antibodies to human type I interferons using division-arrested frozen cells carrying an interferon-regulated reporter-gene.

Lallemand C, Meritet JF, Erickson R, Grossberg SE, Roullet E, Lyon-Caen O, Lebon P, Tovey MG.

J Interferon Cytokine Res. 2008 Jun;28(6):393-404. doi: 10.1089/jir.2007.0142.

PMID:
18593334
2.

Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study.

Boz C, Oger J, Gibbs E, Grossberg SE; Neurologists of the UBC MS Clinic.

Mult Scler. 2007 Nov;13(9):1127-37. Erratum in: Mult Scler. 2008 May;14(4):575.

PMID:
17967840
3.

Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report.

Hartung HP, Polman C, Bertolotto A, Deisenhammer F, Giovannoni G, Havrdova E, Hemmer B, Hillert J, Kappos L, Kieseier B, Killestein J, Malcus C, Comabella M, Pachner A, Schellekens H, Sellebjerg F, Selmaj K, Sorensen PS.

J Neurol. 2007 Jul;254(7):827-37. Epub 2007 Apr 24. Review.

PMID:
17457510
4.

Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Goodin DS, Frohman EM, Hurwitz B, O'Connor PW, Oger JJ, Reder AT, Stevens JC.

Neurology. 2007 Mar 27;68(13):977-84. Erratum in: Neurology. 2007 Aug 14;69(7):712.

PMID:
17389300
5.

Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.

Bertolotto A, Sala A, Caldano M, Capobianco M, Malucchi S, Marnetto F, Gilli F.

J Immunol Methods. 2007 Apr 10;321(1-2):19-31. Epub 2007 Feb 20.

PMID:
17335844
6.

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis.

Sørensen PS, Deisenhammer F, Duda P, Hohlfeld R, Myhr KM, Palace J, Polman C, Pozzilli C, Ross C; EFNS Task Force on Anti-IFN-beta Antibodies in Multiple Sclerosis.

Eur J Neurol. 2005 Nov;12(11):817-27. Review.

PMID:
16241970
7.

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.

Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K; Danish Multiple Sclerosis Study Group.

Neurology. 2005 Jul 12;65(1):33-9. Epub 2005 May 11.

PMID:
15888603
8.

Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis.

Malucchi S, Sala A, Gilli F, Bottero R, Di Sapio A, Capobianco M, Bertolotto A.

Neurology. 2004 Jun 8;62(11):2031-7.

PMID:
15184610
9.

The clinical impact of interferon beta antibodies in relapsing-remitting MS.

Perini P, Calabrese M, Biasi G, Gallo P.

J Neurol. 2004 Mar;251(3):305-9.

PMID:
15015010
11.

Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.

Bertolotto A, Gilli F, Sala A, Capobianco M, Malucchi S, Milano E, Melis F, Marnetto F, Lindberg RL, Bottero R, Di Sapio A, Giordana MT.

Neurology. 2003 Feb 25;60(4):634-9.

PMID:
12601105
12.

Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients.

Vallittu AM, Halminen M, Peltoniemi J, Ilonen J, Julkunen I, Salmi A, Erälinna JP; Finnish Beta-Interferon Study Group.

Neurology. 2002 Jun 25;58(12):1786-90.

PMID:
12084878
13.
14.

The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems.

Grossberg SE, Kawade Y, Kohase M, Yokoyama H, Finter N.

J Interferon Cytokine Res. 2001 Sep;21(9):729-42.

PMID:
11576467
15.
16.

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group.

Neurology. 2001 Jun 26;56(12):1628-36. Erratum in: Neurology 2001 Sep 25;57(6):1146.

PMID:
11425926
17.

The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b.

Rice GP, Paszner B, Oger J, Lesaux J, Paty D, Ebers G.

Neurology. 1999 Apr 12;52(6):1277-9.

PMID:
10214759
18.

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies.

Deisenhammer F, Reindl M, Harvey J, Gasse T, Dilitz E, Berger T.

Neurology. 1999 Apr 12;52(6):1239-43.

PMID:
10214750
19.

A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b.

Pungor E Jr, Files JG, Gabe JD, Do LT, Foley WP, Gray JL, Nelson JW, Nestaas E, Taylor JL, Grossberg SE.

J Interferon Cytokine Res. 1998 Dec;18(12):1025-30.

PMID:
9877445
20.

The expression of potency of neutralizing antibodies for interferons and other cytokines.

Grossberg SE, Kawade Y.

Biotherapy. 1997;10(1):93-8. Review.

PMID:
9261553

Supplemental Content

Support Center